AbbVie Inc. (ETR:4AB)
Germany · Delayed Price · Currency is EUR | Market Cap | 334.51B |
| Revenue (ttm) | 50.83B |
| Net Income (ttm) | 2.00B |
| Shares Out | n/a |
| EPS (ttm) | 1.13 |
| PE Ratio | 167.15 |
| Forward PE | 16.01 |
| Dividend | 5.86 (3.10%) |
| Ex-Dividend Date | Oct 15, 2025 |
| Volume | 82 |
| Average Volume | 578 |
| Open | 189.80 |
| Previous Close | 188.60 |
| Day's Range | 187.60 - 190.40 |
| 52-Week Range | 147.60 - 207.00 |
| Beta | 0.51 |
| RSI | 44.53 |
| Earnings Date | Oct 31, 2025 |
About AbbVie
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancer... [Read more]
Financial Performance
In 2024, AbbVie's revenue was $56.33 billion, an increase of 3.71% compared to the previous year's $54.32 billion. Earnings were $4.24 billion, a decrease of -12.07%.
Financial numbers in USD Financial StatementsNews
Healthcare Q3 Dividend Roundup: I Prefer AbbVie Over Pfizer
Compared to ABBV, PFE's latest dividend declarations and earnings report reveal growth pressure, high payout ratios, and inventory buildup. Read the full analysis now.
VOO, JNJ, ABBV, HD: Large Inflows Detected at ETF
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard S&P 500 ETF (Symbol: VOO) where we have detected an approxima...
$100 Invested In AbbVie 5 Years Ago Would Be Worth This Much Today
AbbVie (NYSE: ABBV) has outperformed the market over the past 5 years by 3.1% on an annualized basis producing an average annual return of 17.03%. Currently, AbbVie has a market capitalization of $38...
Ironwood wins FDA label expansion for bowel disease drug developed with AbbVie
ABBV Receives New Price Target and Overweight Rating from Piper Sandler | ABBV Stock News
ABBV Receives New Price Target and Overweight Rating from Piper Sandler | ABBV Stock News
Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know
Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.
AbbVie (ABBV) Stock Signal: How Did Earnings Impact Its Outlook? - 05 November 2025
Decreased full-year guidance, margin pressure, and high valuations overshadow a strong immunology growth rate. How did earnings impact AbbVie’s outlook?
Decoding AbbVie Inc (ABBV): A Strategic SWOT Insight
Decoding AbbVie Inc (ABBV): A Strategic SWOT Insight
Here Are Tuesday’s Top Wall Street Analyst Research Calls: Apple, AbbVie, Broadcom, CyberArk, Palantir Technologies and More
Pre-Market Futures: The S&P 500 and NASDAQ futures are trading down over 1% on Tuesday, following Palantir’s 6.9% decline despite beating earnings expectations and giving strong forward guidance. Conc...
Citigroup Lowers Price Target for AbbVie (ABBV) to $235 Amidst Neutral Rating | ABBV Stock News
Citigroup Lowers Price Target for AbbVie (ABBV) to $235 Amidst Neutral Rating | ABBV Stock News
What the Options Market Tells Us About AbbVie
Investors with a lot of money to spend have taken a bullish stance on AbbVie (NYSE: ABBV). And retail traders should know. We noticed this today when the trades showed up on publicly available option...
JP Morgan Raises Price Target on AbbVie (ABBV) to $260, Maintains Overweight Rating | ABBV ...
JP Morgan Raises Price Target on AbbVie (ABBV) to $260, Maintains Overweight Rating | ABBV Stock News
Biotech is back. Here's why these rallying stocks belong in your portfolio now.
The volatile sector is seeing greater stability, and these four stocks can profit.
ADP, Snap-on Lead 14 Companies To Announce Annual Increases In First Half Of November
This is my latest article where I provide predictions of upcoming dividend increases from companies with long-term dividend growth histories. The pattern of modest dividend increases continues, with o...
AbbVie (ABBV) Surpasses Q3 Expectations with Strong Revenue Growth
AbbVie (ABBV) Surpasses Q3 Expectations with Strong Revenue Growth
Best Dividend Aristocrats For November 2025
The ProShares S&P 500 Dividend Aristocrats ETF (NOBL) has underperformed SPY in 2025, with a 6.27% YTD gain versus SPY's 17.8%. Despite overall underperformance, select Aristocrats like CAT, CAH, CHRW...
Why AbbVie Stock Flopped on Friday
The market didn't exactly greet the company's latest earnings release with open arms.
AbbVie (ABBV) Exceeds Q3 Expectations, Raises 2025 Outlook
AbbVie (ABBV) Exceeds Q3 Expectations, Raises 2025 Outlook
AbbVie (ABBV) Reports Strong Linzess Sales in Q3
AbbVie (ABBV) Reports Strong Linzess Sales in Q3
Ironwood surges 28% as beneficiary of partner AbbVie's Linzess Q3 sales
Ironwood Pharmaceuticals surged 28% as partner AbbVie said Linzess sales beat forecasts. Read more here.
Looking Into AbbVie Inc's Recent Short Interest
AbbVie Inc's (NYSE: ABBV) short interest as a percent of float has risen 10.87% since its last report. According to exchange reported data, there are now 18.08 million shares sold short , which is 1....
AbbVie raises 2025 EPS guidance and signals strong pipeline milestones into 2026
AbbVie Inc. (ABBV) Q3 2025 Earnings Call Transcript
AbbVie Inc. (ABBV) Q3 2025 Earnings Call October 31, 2025 9:00 AM EDTCompany ParticipantsElizabeth Shea - Senior Vice President of Investor RelationsRobert...
AbbVie Inc (ABBV) Q3 2025 Earnings Call Highlights: Strong Financial Performance Amidst Humira ...
AbbVie Inc (ABBV) Q3 2025 Earnings Call Highlights: Strong Financial Performance Amidst Humira Challenges
Q3 2025 AbbVie Inc Earnings Call Transcript
Q3 2025 AbbVie Inc Earnings Call Transcript